title: Mechanism of inhibitory actions of minocycline and doxycycline on ascitic fluid production induced by mouse fibrosarcoma cells.
abstract: Semisynthetic tetracyclines (TCNs) are used for the management of malignant pleural effusions as sclerosing agents. However, their precise mechanism of actions are uncertain. In the present study, the mechanism of inhibitory effects of minocycline (MINO) and doxycycline (DOXY), on the accumulation of ascitic fluid induced by mouse fibrosarcoma (Meth-A) cells were investigated using male mice. Meth-A cells inoculated intraperitoneally elicited 2.5-4 ml of bloody ascites 10 days after implantation. The production of ascitic fluid was suppressed in a dose-related manner by daily intraperitoneal injections of MINO or DOXY, whereas vehicle (normal saline with 0.01N HCl) did not exert a significant effect. The inhibitory activity of these two substances was quite similar; one mg/mouse of MINO or DOXY inhibited the accumulation of fluid by 87% and 84%, respectively. The survival rate of Meth-A-bearing mice treated with MINO or DOXY was higher than that of the controls. Macroscopic examination of the peritoneal cavity did not reveal any obvious effects, such as adhesions, in mice treated with either MINO or DOXY. In vitro studies showed that MINO and DOXY suppressed Meth-A cell growth with IC50s of 5 microM and 8 microM, respectively. Maximal suppression (95%) was achieved at MINO and DOXY concentrations of 25 microM. The above observations suggest that MINO and DOXY inhibit the accumulation of ascites by a direct effect on Meth-A cell growth. Therefore, it appears that TCNs injected into the pleural cavity to manage malignant effusions in man exert their activity, at least in part, by suppressing malignant cell growth.
authors.affiliation: Institute for Growth Science, Tokyo Women's Medical College, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Wakai
authors.forename: E
authors.initials: E
authors.lastname: Ohmura
authors.forename: T
authors.initials: T
authors.lastname: Satoh
authors.forename: H
authors.initials: H
authors.lastname: Murakami
authors.forename: O
authors.initials: O
authors.lastname: Isozaki
authors.forename: N
authors.initials: N
authors.lastname: Emoto
authors.forename: H
authors.initials: H
authors.lastname: Demura
authors.forename: K
authors.initials: K
authors.lastname: Shizume
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
mesh_terms: D000818:Animals; D001201:Ascites / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008911:Minocycline / Q000494:pharmacology / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013754:Tetracyclines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D013754:Tetracyclines; D008911:Minocycline; D004318:Doxycycline